Serds | List of Frontiers open access articles

Review

Published on 10 May 2024

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer

in Breast Cancer

Baha’ Sharaf
Abdelrahman Hajahjeh
Hira Bani Hani
Hikmat Abdel-Razeq

Frontiers in Oncology

doi 10.3389/fonc.2024.1385577

11,255 views
17 citations

Review

Published on 21 Sep 2023

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future

in Pharmacology of Anti-Cancer Drugs

Jiaqi Yao
Yiran Tao
Zelin Hu
Junjie Li
Ziyi Xue
Ya Zhang
Yi Lei

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1225951

7,221 views
8 citations

Review

Published on 10 Apr 2025

Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action

in Oncology Reviews: Reviews

Nayoung Kim
Kiven Erique Lukong

Oncology Reviews

doi 10.3389/or.2025.1564642

16,519 views
26 citations

Review

Published on 22 Jan 2026

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region

in Breast Cancer

Ahmed Alshehri
Abdullah Khalaf Altwairgi
Abdulwahab AlTourah
Ahmed Alwbari
Aref Chehal
Francois Calaud
Hashem Al-Hashem
Husam Marashi
Sherif Elsamany
Syed Hammad Tirmazy

Frontiers in Oncology

doi 10.3389/fonc.2025.1706670

1,441 views

Systematic Review

Published on 07 May 2019

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review

in Women's Cancer

Willem Jan van Weelden
Leon F. A. G. Massuger
ENITEC
Johanna M. A. Pijnenborg
Andrea Romano

Frontiers in Oncology

doi 10.3389/fonc.2019.00359

37,514 views
101 citations

Original Research

Accepted on 02 Feb 2026

Patterns of Neurologic and Psychiatric Toxicity Burden of Different Endocrine Therapeutics for Breast Cancer: A Global Pharmacovigilance Study Based on FAERS and VigiAccess

in Pharmacoepidemiology

Guoqiang Li
Mengqi Yang
Lei Zhang
Xin Li
Xiaoliang Wu
Feng Peng
Yajie Liu

Frontiers in Pharmacology

141 views

Articles

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future

Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review

Patterns of Neurologic and Psychiatric Toxicity Burden of Different Endocrine Therapeutics for Breast Cancer: A Global Pharmacovigilance Study Based on FAERS and VigiAccess